KR102834408B1 - Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체 - Google Patents
Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체Info
- Publication number
- KR102834408B1 KR102834408B1 KR1020217011213A KR20217011213A KR102834408B1 KR 102834408 B1 KR102834408 B1 KR 102834408B1 KR 1020217011213 A KR1020217011213 A KR 1020217011213A KR 20217011213 A KR20217011213 A KR 20217011213A KR 102834408 B1 KR102834408 B1 KR 102834408B1
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- alkyl
- ring
- mmol
- equiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733061P | 2018-09-18 | 2018-09-18 | |
| US62/733,061 | 2018-09-18 | ||
| US201862749655P | 2018-10-23 | 2018-10-23 | |
| US62/749,655 | 2018-10-23 | ||
| US201962810911P | 2019-02-26 | 2019-02-26 | |
| US62/810,911 | 2019-02-26 | ||
| US201962883120P | 2019-08-06 | 2019-08-06 | |
| US201962883121P | 2019-08-06 | 2019-08-06 | |
| US62/883,120 | 2019-08-06 | ||
| US62/883,121 | 2019-08-06 | ||
| PCT/US2019/051590 WO2020061101A1 (en) | 2018-09-18 | 2019-09-17 | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210060556A KR20210060556A (ko) | 2021-05-26 |
| KR102834408B1 true KR102834408B1 (ko) | 2025-07-15 |
Family
ID=68084982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217011213A Active KR102834408B1 (ko) | 2018-09-18 | 2019-09-17 | Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체 |
| KR1020217011212A Pending KR20210060555A (ko) | 2018-09-18 | 2019-09-17 | Src 호몰로지-2 포스파타아제 억제제로서의 융합된 삼환식 고리 유도체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217011212A Pending KR20210060555A (ko) | 2018-09-18 | 2019-09-17 | Src 호몰로지-2 포스파타아제 억제제로서의 융합된 삼환식 고리 유도체 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US11459340B2 (enExample) |
| EP (2) | EP3853234B1 (enExample) |
| JP (2) | JP7337174B2 (enExample) |
| KR (2) | KR102834408B1 (enExample) |
| CN (2) | CN113227103B (enExample) |
| AU (2) | AU2019344899B2 (enExample) |
| BR (1) | BR112021005082A2 (enExample) |
| CA (2) | CA3113234A1 (enExample) |
| CL (1) | CL2021000628A1 (enExample) |
| CO (1) | CO2021004436A2 (enExample) |
| CR (1) | CR20210175A (enExample) |
| DK (1) | DK3853234T3 (enExample) |
| ES (1) | ES3036496T3 (enExample) |
| FI (1) | FI3853234T3 (enExample) |
| MX (1) | MX2021003158A (enExample) |
| PH (1) | PH12021550604A1 (enExample) |
| PL (1) | PL3853234T3 (enExample) |
| PT (1) | PT3853234T (enExample) |
| SA (1) | SA521421505B1 (enExample) |
| SG (1) | SG11202102679QA (enExample) |
| TW (1) | TWI827677B (enExample) |
| WO (2) | WO2020061103A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12019500056B1 (en) | 2016-07-12 | 2024-01-31 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| SG11201906412SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors |
| BR112019015075A2 (pt) | 2017-01-23 | 2020-03-10 | Revolution Medicines, Inc. | Compostos bicíclicos como inibidores de shp2 alostéricos |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| WO2019067843A1 (en) | 2017-09-29 | 2019-04-04 | Relay Therapeutics, Inc. | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 |
| SG11202002941WA (en) * | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| CA3084058A1 (en) | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| CN117263942A (zh) | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN113365988B (zh) * | 2019-01-31 | 2023-10-03 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
| WO2021043077A1 (zh) * | 2019-09-06 | 2021-03-11 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡嗪化合物、其制备方法和用途 |
| WO2021061515A1 (en) * | 2019-09-23 | 2021-04-01 | Synblia Therapeutics, Inc. | Shp2 inhibitors and uses thereof |
| WO2021061706A1 (en) | 2019-09-24 | 2021-04-01 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
| PE20230249A1 (es) | 2019-11-08 | 2023-02-07 | Revolution Medicines Inc | Compuestos de heteroarilo biciclicos y usos de estos |
| EP4076667A1 (en) | 2019-12-20 | 2022-10-26 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
| EP4169913A4 (en) * | 2020-06-22 | 2024-10-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF |
| WO2022042331A1 (zh) * | 2020-08-25 | 2022-03-03 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物及其制备方法和用途 |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| AU2021345111B2 (en) | 2020-09-15 | 2025-11-27 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| CN117098537A (zh) * | 2020-12-11 | 2023-11-21 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| CA3201612A1 (en) * | 2020-12-11 | 2022-06-16 | Leenus MARTIN | Combination therapies for the treatment of cancer |
| CN117083283A (zh) * | 2020-12-11 | 2023-11-17 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| CN117120449A (zh) * | 2020-12-11 | 2023-11-24 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| AU2021396397A1 (en) * | 2020-12-11 | 2023-07-27 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| KR20230154793A (ko) * | 2020-12-11 | 2023-11-09 | 에라스카, 아이엔씨. | 암 치료를 위한 병용 요법 |
| IL303782A (en) * | 2020-12-18 | 2023-08-01 | Genzyme Corp | Process for preparing shp2 inhibitors |
| CN116848121A (zh) * | 2020-12-18 | 2023-10-03 | 建新公司 | 制备shp2抑制剂的方法 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN117083285A (zh) * | 2021-03-31 | 2023-11-17 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
| AR125782A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| WO2022271966A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| US20240285624A1 (en) * | 2021-06-24 | 2024-08-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| TW202317124A (zh) * | 2021-06-24 | 2023-05-01 | 美商艾瑞斯卡公司 | Erk1/2及shp2抑制劑之組合療法 |
| MX2024000271A (es) * | 2021-07-09 | 2024-01-31 | Kanaph Therapeutics Inc | Inhibidor de shp2 y uso del mismo. |
| EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023044065A1 (en) * | 2021-09-17 | 2023-03-23 | Erasca, Inc. | Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy |
| WO2023059771A1 (en) * | 2021-10-06 | 2023-04-13 | Erasca, Inc. | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| KR20250040894A (ko) | 2022-05-25 | 2025-03-25 | 이케나 온콜로지, 인코포레이티드 | Mek 억제제 및 이의 용도 |
| AU2023285116A1 (en) | 2022-06-10 | 2024-12-19 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024042361A1 (en) * | 2022-08-24 | 2024-02-29 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| EP4646209A1 (en) * | 2023-01-06 | 2025-11-12 | Erasca, Inc. | Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| EP4688790A1 (en) | 2023-04-07 | 2026-02-11 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (385)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| JPS62135835A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135832A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135830A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62135834A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62136654A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JPS62136651A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
| JPS62136650A (ja) | 1985-12-11 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62206545A (ja) | 1986-03-07 | 1987-09-11 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| GB8729614D0 (en) | 1987-12-18 | 1988-02-03 | Beecham Group Plc | Novel compounds |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| US5360459A (en) | 1991-05-13 | 1994-11-01 | The Lubrizol Corporation | Copper-containing organometallic complexes and concentrates and diesel fuels containing same |
| JPH05196976A (ja) | 1991-11-18 | 1993-08-06 | Toshiba Corp | 有機非線形光学材料 |
| JPH05181221A (ja) | 1991-12-27 | 1993-07-23 | Konica Corp | ハロゲン化銀写真感光材料 |
| GB9201755D0 (en) | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
| FR2687932A1 (fr) | 1992-02-27 | 1993-09-03 | Oreal | Dispersion huile-dans-l'eau susceptible de former des films composites. |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AU3785597A (en) | 1996-08-14 | 1998-03-06 | Takeda Chemical Industries Ltd. | Cyclic urea compounds, their production and use as herbicides |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6117973A (en) | 1997-02-24 | 2000-09-12 | Georgia Tech Research Corp. | PNA monomers with electron donor or acceptor |
| FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| JP2000072695A (ja) | 1998-08-24 | 2000-03-07 | Sumitomo Pharmaceut Co Ltd | 環状化合物 |
| CN1242995C (zh) | 1999-05-21 | 2006-02-22 | 比奥维特罗姆股份公司 | 化合物,它们的用途和制备方法 |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| BR0012984A (pt) | 1999-08-04 | 2002-07-16 | Millennium Pharm Inc | Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| ATE312100T1 (de) | 1999-09-28 | 2005-12-15 | Eisai Co Ltd | Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| JP4548761B2 (ja) | 2000-06-15 | 2010-09-22 | 富士フイルムホールディングス株式会社 | 潤滑剤組成物 |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE10032633A1 (de) | 2000-07-05 | 2002-01-17 | Bayer Ag | Verfahren zum Auffinden von Hemmstoffen der Protoporphyrinogen-Oxidase |
| JP2002122954A (ja) | 2000-08-08 | 2002-04-26 | Fuji Photo Film Co Ltd | 感光性ハロゲン化銀写真乳剤、これを含有するハロゲン化銀写真感光材料および感光性ハロゲン化銀写真乳剤の感度向上方法 |
| WO2002015910A1 (en) | 2000-08-18 | 2002-02-28 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
| AU2001294865A1 (en) | 2000-09-30 | 2002-04-15 | Loctite | Low shrinkage thermosetting resin compositions and methods of use therefor |
| US6963001B2 (en) | 2000-09-30 | 2005-11-08 | Henkel Corporation | Low shrinkage thermosetting resin compositions and methods of use therefor |
| US20020173524A1 (en) | 2000-10-11 | 2002-11-21 | Tularik Inc. | Modulation of CCR4 function |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| SE0103646D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic chroman compounds |
| MXPA03006250A (es) | 2001-01-16 | 2003-09-22 | Astrazeneca Ab | Compuestos heterociclicos terapeuticos. |
| BR0206513A (pt) | 2001-01-16 | 2004-01-06 | Astrazeneca Ab | Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos |
| IL157638A0 (en) | 2001-03-01 | 2004-03-28 | Shionogi & Co | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| ES2332090T3 (es) | 2001-04-06 | 2010-01-26 | Biocryst Pharmaceuticals, Inc. | Compuestos biarilicos como inhibidores de serina proteasa. |
| WO2003003008A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Chemical libraries useful for drug discovery processes |
| WO2003003009A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| BR0307544A (pt) | 2002-02-01 | 2004-12-07 | Ariad Gene Therapeutics Inc | Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos |
| JP4201716B2 (ja) | 2002-03-05 | 2008-12-24 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害剤 |
| US20050247001A1 (en) | 2002-03-15 | 2005-11-10 | Nuevolution A/S | Building block forming a c-c or a c-hetero atom bond uponreaction |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| WO2004017922A2 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
| US7071355B2 (en) | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| GB0306430D0 (en) | 2003-03-20 | 2003-04-23 | Bp Chem Int Ltd | Polymerisation and oligomerisation catalysts |
| EP1628666B1 (en) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| US20070010529A1 (en) | 2003-05-19 | 2007-01-11 | Kanji Takahashi | Nitrogenous heterocyclic compounds and medical use thereof |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| JP4231379B2 (ja) | 2003-10-15 | 2009-02-25 | 富士フイルム株式会社 | 潤滑剤組成物 |
| JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| DE10355066A1 (de) | 2003-11-25 | 2005-06-23 | Basf Ag | Verfahren zur asymmetrischen Synthese |
| US7632946B2 (en) | 2004-02-06 | 2009-12-15 | Abbott Laboratories | Naphthyridine-based antibacterial compositions |
| JP2005263787A (ja) | 2004-02-17 | 2005-09-29 | Ishihara Sangyo Kaisha Ltd | アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
| US7897607B2 (en) | 2004-04-07 | 2011-03-01 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| EP1595888A1 (en) | 2004-05-11 | 2005-11-16 | Degussa AG | Cycloolefin phosphine ligands and their use in catalysis |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| GB0415879D0 (en) | 2004-07-15 | 2004-08-18 | Bp Chem Int Ltd | Polymerisation catalyst |
| GB0418022D0 (en) | 2004-08-12 | 2004-09-15 | Bp Chem Int Ltd | Polymerisation and oligomerisation catalyst |
| KR20200019263A (ko) | 2004-09-02 | 2020-02-21 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| GB0420396D0 (en) | 2004-09-14 | 2004-10-13 | Bp Chem Int Ltd | Polyolefins |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| WO2006061094A1 (en) | 2004-12-11 | 2006-06-15 | Merck Patent Gmbh | Liquid crystal compounds, liquid crystal medium and liquid crystal display |
| JP2008527030A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| JP4749000B2 (ja) | 2005-02-22 | 2011-08-17 | 富士フイルム株式会社 | グリース組成物 |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| WO2006098380A1 (ja) | 2005-03-15 | 2006-09-21 | Fujifilm Corporation | 円盤状化合物を用いた表面処理法、表面処理用（潤滑）組成物及び表面処理された物品 |
| US20060156481A1 (en) | 2005-03-22 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| WO2006105291A2 (en) | 2005-03-31 | 2006-10-05 | Third-Order Nanotechnologies, Inc. | Heterocyclical chromophore architectures with novel electronic acceptor systems |
| AU2006237365B2 (en) | 2005-04-21 | 2012-09-20 | Merck Serono Sa | 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2 |
| AU2006239632B2 (en) | 2005-04-25 | 2012-03-15 | Merck Patent Gmbh | Novel AZA- heterocycles serving as kinase inhibitors |
| WO2006119800A1 (en) | 2005-05-09 | 2006-11-16 | Technische Universität Braunschweig | Light emitting compound for electroluminescent applications |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7728008B2 (en) | 2005-06-27 | 2010-06-01 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| WO2007002635A2 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| WO2007011721A1 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| JP2007056213A (ja) | 2005-08-26 | 2007-03-08 | Fujifilm Corp | 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材 |
| KR101347102B1 (ko) | 2005-10-19 | 2014-01-03 | 그뤼넨탈 게엠베하 | 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도 |
| FR2892859B1 (fr) | 2005-10-27 | 2008-06-06 | Commissariat Energie Atomique | Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications |
| WO2007062222A2 (en) | 2005-11-22 | 2007-05-31 | University Of South Florida | Inhibition of cell proliferation |
| WO2007064869A2 (en) | 2005-12-01 | 2007-06-07 | Yale University | Catalysts for aryl sulfide synthesis and method of producing aryl sulfides |
| JP2008007634A (ja) | 2006-06-29 | 2008-01-17 | Fujifilm Corp | 潤滑剤組成物 |
| JP2010501570A (ja) | 2006-08-23 | 2010-01-21 | エックスティーエル バイオファーマシューティカルズ リミテッド | ４−チオ置換キノリンおよびナフチリジン化合物 |
| KR101436179B1 (ko) | 2006-09-02 | 2014-09-01 | 메르크 파텐트 게엠베하 | 반응성 메소젠의 배향을 위한 입자 빔 방법 |
| WO2008118626A2 (en) | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibitors of jnk and methods for identifying inhibitors of jnk |
| US7956020B2 (en) | 2007-03-29 | 2011-06-07 | Fujifilm Corporation | Lubricant composition, mechanical element, and method for producing triazine derivatives |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| CA2934114A1 (en) | 2007-06-12 | 2008-12-18 | Achaogen, Inc. | Antibacterial agents |
| US8063165B2 (en) | 2007-06-18 | 2011-11-22 | Bridgestone Corporation | Functional polymers prepared with sulfur-containing initiators |
| JP2009013314A (ja) | 2007-07-06 | 2009-01-22 | Toyo Ink Mfg Co Ltd | 光硬化型インキ |
| ES2545121T3 (es) | 2007-08-21 | 2015-09-08 | Senomyx, Inc. | Compuestos que inhiben (bloquean) el sabor amargo en composiciones, y uso de los mismos |
| US8143276B2 (en) | 2007-08-22 | 2012-03-27 | Xtl Biopharmaceuticals Ltd. | 4-thio substituted quinoline and naphthyridine compounds |
| WO2009026720A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| WO2009030318A1 (de) | 2007-08-29 | 2009-03-12 | Merck Patent Gmbh | Flüssigkristallanzeige |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| ES2446932T3 (es) | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
| US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| BRPI0817897A2 (pt) | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| WO2009078813A1 (en) | 2007-12-19 | 2009-06-25 | Nanyang Technological University | Method of forming oseltamivir and derivatives thereof |
| EP2098226A1 (de) | 2008-03-06 | 2009-09-09 | Forschungsverbund Berlin e.V. | AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| JP5847580B2 (ja) | 2008-07-28 | 2016-01-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 液晶ディスプレイ |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| CN102264866B (zh) | 2008-12-22 | 2014-06-18 | 默克专利股份有限公司 | 液晶显示器 |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| DE102010006691A1 (de) | 2009-02-06 | 2010-10-28 | Merck Patent Gmbh | Flüssigkristallines Medium und Flüssigkristallanzeige |
| US20120077959A1 (en) | 2009-02-16 | 2012-03-29 | Zhang X Peter | Asymmetric Cobalt-Catalyzed Cyclopropanation With Succinimidyl Diazoacetate |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| JP2010217692A (ja) | 2009-03-18 | 2010-09-30 | Konica Minolta Holdings Inc | 表示素子 |
| ES2548571T3 (es) | 2009-04-02 | 2015-10-19 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Derivados de imidazo[2,1-b][1,3,4]tiadiazol |
| EP2414317A2 (en) | 2009-04-03 | 2012-02-08 | The Scripps Research Institute | Palladium-catalyzed ortho-fluorination |
| DE102010012900A1 (de) | 2009-04-23 | 2010-11-25 | Merck Patent Gmbh | Flüssigkristallanzeige |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| WO2011005355A1 (en) | 2009-05-07 | 2011-01-13 | Achaogen, Inc. | Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria |
| WO2010147969A2 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| US20120232108A1 (en) | 2009-06-16 | 2012-09-13 | Xianhai Huang | Gamma secretase modulators |
| WO2010147975A1 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| CA2937222C (en) | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| WO2010148422A1 (en) | 2009-06-25 | 2010-12-29 | Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for treating parasitic infestations |
| WO2011022502A1 (en) | 2009-08-18 | 2011-02-24 | Georgetown University | Boronic acid compositions and methods related to cancer |
| JP5728683B2 (ja) | 2009-09-04 | 2015-06-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン |
| EP2292720A1 (en) | 2009-09-08 | 2011-03-09 | Merck Patent GmbH | Liquid-crystal display |
| WO2011056929A1 (en) | 2009-11-04 | 2011-05-12 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
| KR20110088098A (ko) | 2010-01-28 | 2011-08-03 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| CA2790176A1 (en) | 2010-02-18 | 2011-08-25 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Triazolo [4, 5 - b] pyridin derivatives |
| KR101939704B1 (ko) | 2010-03-01 | 2019-01-17 | 지티엑스, 인코포레이티드 | 암 치료용 화합물 |
| KR20110101444A (ko) | 2010-03-08 | 2011-09-16 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 포함하는 유기 발광 소자 |
| KR20110104765A (ko) | 2010-03-17 | 2011-09-23 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| CA2812526A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| CA2800618C (en) | 2010-05-26 | 2018-08-28 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| CA2800401C (en) | 2010-06-03 | 2020-09-15 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| KR101764952B1 (ko) | 2010-07-29 | 2017-08-03 | 리겔 파마슈티칼스, 인크. | Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법 |
| WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012020215A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| WO2012020357A1 (en) | 2010-08-09 | 2012-02-16 | Advinus Therapeutics Ltd. | Acetamide compounds, their process and pharmaceutical application |
| EP2606033A1 (de) | 2010-08-20 | 2013-06-26 | Grünenthal GmbH | Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors |
| RU2013121799A (ru) | 2010-10-14 | 2014-11-20 | Конинклейке Филипс Электроникс Н.В. | Набор для претаргетинга, способ и агенты, применяемые в нем |
| US9394290B2 (en) | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| US20120108819A1 (en) | 2010-10-28 | 2012-05-03 | Basf Se | N-Heterocyclic Carbene Complexes, Their Preparation And Use |
| EP2632929A4 (en) | 2010-10-28 | 2014-03-26 | Basf Se | N-heterocyclic carbene complexes and their preparation and use |
| KR20120045905A (ko) | 2010-11-01 | 2012-05-09 | 한국화학연구원 | 헤테로고리 축합된 피리도 화합물 및 이의 제조방법 |
| US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| US20140031547A1 (en) | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
| EP2654796A1 (en) | 2010-12-21 | 2013-10-30 | Koninklijke Philips N.V. | Agents for clearing biomolecules from circulation |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| JP5618815B2 (ja) | 2010-12-24 | 2014-11-05 | 富士フイルム株式会社 | 感活性光線性又は感放射線性樹脂組成物、並びに、この組成物を用いた感活性光線性又は感放射線性膜及びパターン形成方法 |
| TWI450891B (zh) | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| WO2012116135A2 (en) | 2011-02-24 | 2012-08-30 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| EP2681196B1 (en) | 2011-03-04 | 2015-09-09 | Life Technologies Corporation | Compounds and methods for conjugation of biomolecules |
| DE102012003796A1 (de) | 2011-03-18 | 2012-09-20 | Merck Patent Gmbh | Flüssigkristallines Medium |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| EP3260518B1 (de) | 2011-03-29 | 2019-12-25 | Merck Patent GmbH | Flüssigkristallines medium |
| WO2013058825A1 (en) | 2011-04-07 | 2013-04-25 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
| EP2522369A1 (en) | 2011-05-09 | 2012-11-14 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| RS58718B1 (sr) | 2011-05-12 | 2019-06-28 | Proteostasis Therapeutics Inc | Regulatori proteostaze |
| EP2709666B1 (en) | 2011-05-16 | 2021-07-14 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| JP5782836B2 (ja) | 2011-05-27 | 2015-09-24 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子材料、有機エレクトロルミネッセンス素子、表示装置、照明装置、並びに化合物 |
| WO2012167171A2 (en) | 2011-06-03 | 2012-12-06 | Massachusetts Institute Of Technology | Z-selective ring-closing metathesis reactions |
| KR20140063579A (ko) | 2011-06-28 | 2014-05-27 | 메르크 파텐트 게엠베하 | 유기 반도체로서의 인다세노 유도체 |
| CN103619993B (zh) | 2011-07-07 | 2016-10-12 | 默克专利股份有限公司 | 液晶介质 |
| US20140131628A1 (en) | 2011-07-08 | 2014-05-15 | Merck Patent Gmbh | Conjugated polymers |
| US9550000B2 (en) | 2011-09-09 | 2017-01-24 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| EP2615083A1 (en) | 2012-01-10 | 2013-07-17 | Studiengesellschaft Kohle mbH | Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst |
| JP5814141B2 (ja) | 2012-01-23 | 2015-11-17 | ユー・ディー・シー アイルランド リミテッド | 合成法、その合成法を用いて合成された化合物および有機電界発光素子 |
| CN104136576B (zh) | 2012-02-22 | 2020-10-16 | 默克专利股份有限公司 | 液晶介质 |
| CN104254581B (zh) | 2012-04-03 | 2016-12-14 | 3M创新有限公司 | 包含光产碱剂的可交联组合物 |
| JP6109295B2 (ja) | 2012-04-20 | 2017-04-05 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | Ｎ−シクロアルキル−ｎ−［（ヘテロシクリルフェニル）メチレン］−（チオ）カルボキサミド誘導体 |
| FR2992317B1 (fr) | 2012-06-22 | 2016-05-13 | Diverchim | Procede de preparation de peptides chiraux |
| US8575283B1 (en) | 2012-06-28 | 2013-11-05 | Formosa Plastics Corporation, U.S.A. | Heterocyclic organic compounds as electron donors for polyolefin catalysts |
| WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| KR102189940B1 (ko) | 2012-09-04 | 2020-12-14 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 이미다졸린 유도체, 이의 제조 방법, 및 이들의 의약에서의 용도 |
| IN2015DN02008A (enExample) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| KR101677866B1 (ko) | 2012-10-29 | 2016-11-18 | 코니카 미놀타 가부시키가이샤 | 위상차 필름, 원편광판 및 화상 표시 장치 |
| KR20150084994A (ko) | 2012-11-16 | 2015-07-22 | 바스프 에스이 | 플루오로중합체 씰 상용성을 개선하기 위한 에폭시드 화합물을 포함하는 윤활제 조성물 |
| US9676778B2 (en) * | 2012-11-20 | 2017-06-13 | Principia Biopharma Inc. | Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| WO2014081301A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| EP2922574B1 (en) | 2012-11-22 | 2023-05-17 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
| EP2931836B1 (en) | 2012-12-12 | 2020-03-18 | Merck Patent GmbH | Liquid-crystalline medium |
| JP6335428B2 (ja) | 2012-12-21 | 2018-05-30 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| WO2014106524A2 (de) | 2013-01-03 | 2014-07-10 | Merck Patent Gmbh | Materialien für elektronische vorrichtungen |
| WO2014122933A1 (ja) | 2013-02-08 | 2014-08-14 | ソニー株式会社 | 有機エレクトロルミネッセンス素子 |
| EP2956441A4 (en) | 2013-02-18 | 2016-11-02 | Scripps Research Inst | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL |
| US9487472B2 (en) | 2013-02-26 | 2016-11-08 | President And Fellows Of Harvard College | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer |
| WO2014134127A1 (en) | 2013-02-26 | 2014-09-04 | Northeastern University | Cannabinergic nitrate esters and related analogs |
| WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
| US9290528B1 (en) | 2013-03-15 | 2016-03-22 | University Of Kentucky Research Foundation | Light-activated compounds |
| JP5902641B2 (ja) | 2013-03-27 | 2016-04-13 | 富士フイルム株式会社 | 光干渉顔料およびその製造方法 |
| EP2981522A4 (en) | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | PPAR AGONISTS |
| WO2014166584A1 (de) | 2013-04-08 | 2014-10-16 | Merck Patent Gmbh | Organische elektrolumineszenzvorrichtung mit thermisch aktiviertem verzögertem fluoreszenzmaterial |
| US20160093812A1 (en) | 2013-04-08 | 2016-03-31 | Merck Patent Gmbh | Organic electroluminescent device |
| US9522881B2 (en) | 2013-04-26 | 2016-12-20 | Indiana University Research And Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) |
| JP2014232188A (ja) | 2013-05-29 | 2014-12-11 | コニカミノルタ株式会社 | セルロースアシレートフィルム、円偏光板及び画像表示装置 |
| WO2015003137A1 (en) | 2013-07-03 | 2015-01-08 | University Of Connecticut | Polymerization of diene monomers |
| US10478445B2 (en) | 2013-07-03 | 2019-11-19 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| CA2953482A1 (en) | 2013-07-03 | 2015-01-08 | Indiana University Research & Technology Corporation | Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| KR102252761B1 (ko) | 2013-08-02 | 2021-05-18 | 메르크 파텐트 게엠베하 | 액정 매질 |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
| EP2857405A1 (en) | 2013-10-01 | 2015-04-08 | Studiengesellschaft Kohle mbH | Process for the trans-selective hydroboration of internal alkynes |
| KR20160063366A (ko) | 2013-10-21 | 2016-06-03 | 메르크 파텐트 게엠베하 | Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도 |
| JP6088995B2 (ja) | 2013-10-24 | 2017-03-01 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| JP6522313B2 (ja) | 2013-10-24 | 2019-05-29 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| KR101537860B1 (ko) | 2013-11-22 | 2015-07-20 | 롯데케미칼 주식회사 | 내감마선 성능이 향상된 폴리카보네이트 수지 조성물 및 이를 이용한 성형품 |
| JP6215674B2 (ja) | 2013-11-29 | 2017-10-18 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| JP6309834B2 (ja) | 2013-12-11 | 2018-04-11 | 株式会社Adeka | 着色性組成物 |
| JP2015163671A (ja) | 2013-12-13 | 2015-09-10 | 株式会社Adeka | ラジカル重合性組成物 |
| US10131841B2 (en) | 2013-12-16 | 2018-11-20 | Merck Patent Gmbh | Liquid-crystalline medium |
| US10020455B2 (en) | 2014-01-07 | 2018-07-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate platinum and palladium complex emitters containing phenyl-pyrazole and its analogues |
| WO2015106025A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| EP3094627B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| EP3094629B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| KR20150091942A (ko) | 2014-02-04 | 2015-08-12 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| JP6313604B2 (ja) | 2014-02-05 | 2018-04-18 | 富士フイルム株式会社 | 感活性光線性又は感放射線性樹脂組成物、感活性光線性又は感放射線性膜、感活性光線性又は感放射線性膜を備えたマスクブランクス、パターン形成方法、及び電子デバイスの製造方法 |
| EP3110794A1 (en) | 2014-02-27 | 2017-01-04 | Merck Patent GmbH | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| SI3143011T1 (sl) | 2014-05-13 | 2021-08-31 | F. Hoffmann-La Roche Ag | Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva |
| AU2015258904A1 (en) | 2014-05-16 | 2016-11-17 | Liqwd, Inc. | Keratin treatment formulations and methods |
| MX375153B (es) | 2014-05-19 | 2025-03-06 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelminticos. |
| AU2015269598B2 (en) | 2014-06-05 | 2019-11-14 | Merck Patent Gmbh | Novel quinoline derivatives and their use in neurodegenerative diseases |
| WO2016010485A1 (en) | 2014-07-16 | 2016-01-21 | Agency For Science, Technology And Research | Donor-acceptor polymers |
| US9818959B2 (en) | 2014-07-29 | 2017-11-14 | Arizona Board of Regents on behlaf of Arizona State University | Metal-assisted delayed fluorescent emitters containing tridentate ligands |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP2985334B1 (en) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Liquid-crystalline medium |
| EP3188271B1 (en) | 2014-08-26 | 2022-05-04 | Idemitsu Kosan Co., Ltd | Organic electroluminescent element and electronic device |
| EP2991153B1 (en) | 2014-08-28 | 2023-08-23 | Samsung Electronics Co., Ltd. | Composite electrolyte and lithium battery including the same |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| CA2968884A1 (en) | 2014-12-10 | 2016-06-16 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| KR102384224B1 (ko) | 2014-12-30 | 2022-04-08 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| WO2016145383A1 (en) | 2015-03-11 | 2016-09-15 | Board Of Regents, University Of Texas System | Mth1 inhibitors for treating disease |
| KR102434696B1 (ko) | 2015-03-13 | 2022-08-22 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| KR102114536B1 (ko) | 2015-05-07 | 2020-05-22 | 브리스톨-마이어스 스큅 컴퍼니 | RORγ 조정제로서의 트리시클릭 술폰 |
| US9458308B1 (en) | 2015-05-12 | 2016-10-04 | Lotte Chemical Corporation | Polycarbonate resin composition with increased gamma-radiation resistant property and molded article using the same |
| US9879039B2 (en) | 2015-06-03 | 2018-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues |
| ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| FR3037952B1 (fr) | 2015-06-24 | 2019-01-25 | Compagnie Generale Des Etablissements Michelin | Procede de synthese d'oximes aromatiques |
| EP3112440B1 (en) | 2015-07-02 | 2019-07-24 | Merck Patent GmbH | Liquid-crystal medium |
| WO2017015562A1 (en) | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| GB201514015D0 (en) | 2015-08-07 | 2015-09-23 | Arnér Elias S J And Dept Of Health And Human Services | Novel pyridazinones and their use in the treatment of cancer |
| GB201514018D0 (en) | 2015-08-07 | 2015-09-23 | Arnér Elias S J And United States Of America Asrepresented By The Sec Dep Of Health And Human Servic | Novel tricyclic compounds and their use in the treatment of cancer |
| CA2995325A1 (en) | 2015-08-12 | 2017-02-16 | Mochida Pharmaceutical Co., Ltd. | Isothiazole derivative |
| EP3133078B1 (en) | 2015-08-18 | 2019-01-30 | Samsung Electronics Co., Ltd. | Organometallic compound and organic light-emitting device including the same |
| KR101796227B1 (ko) | 2015-08-21 | 2017-11-10 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10240085B2 (en) | 2015-08-27 | 2019-03-26 | Samsung Electronics Co., Ltd. | Thin film and organic light-emitting device including the same |
| KR102542465B1 (ko) | 2015-09-22 | 2023-06-12 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| SE541053C2 (sv) | 2015-09-30 | 2019-03-19 | Epiroc Rock Drills Ab | System och förfarande för borrplansgenerering, borrigg, datorprogram samt datorprogramprodukt |
| US20180305334A1 (en) | 2015-10-14 | 2018-10-25 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| EP3162875B1 (en) | 2015-10-30 | 2018-05-23 | Merck Patent GmbH | Polymerisable compounds and the use thereof in liquid-crystal displays |
| EP3371172B1 (en) | 2015-11-02 | 2021-10-20 | Genase Therapeutics B.V. | Tetrahydroindazoles and medical uses thereof |
| EP3377481A1 (en) * | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| KR20170069342A (ko) | 2015-12-10 | 2017-06-21 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CN106892924B (zh) | 2015-12-17 | 2021-01-08 | 四川科伦博泰生物医药股份有限公司 | 短效苯并二氮*衍生物、其制备方法及其用途 |
| KR20170075118A (ko) | 2015-12-22 | 2017-07-03 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102579752B1 (ko) | 2015-12-22 | 2023-09-19 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10336772B2 (en) | 2015-12-28 | 2019-07-02 | Samsung Electronics Co., Ltd. | Bicarbazole compound, material for organic light-emitting device including bicarbazole compound, and organic light-emitting device including bicarbazole compound |
| KR102396293B1 (ko) | 2015-12-29 | 2022-05-11 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102419178B1 (ko) | 2015-12-29 | 2022-07-11 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2017117239A1 (en) | 2015-12-30 | 2017-07-06 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
| EP3190164B1 (en) | 2016-01-05 | 2019-07-24 | Samsung Electronics Co., Ltd | Composition, thin film including the composition, and organic light-emitting device including the composition or the thin film |
| KR102633852B1 (ko) | 2016-01-25 | 2024-02-07 | 삼성디스플레이 주식회사 | 카바졸계 화합물 및 이를 포함한 유기 발광 소자 |
| WO2017137047A1 (en) | 2016-02-08 | 2017-08-17 | Aaa Chemistry Aps | Arylation of aliphatic amines |
| KR102628850B1 (ko) | 2016-03-07 | 2024-01-25 | 삼성디스플레이 주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| EP3426654B1 (en) | 2016-03-09 | 2021-10-20 | President and Fellows of Harvard College | Direct palladium-catalyzed aromatic fluorination |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| CN108780273B (zh) | 2016-03-31 | 2022-06-28 | Dnp精细化工股份有限公司 | 感光性着色树脂组合物、滤色器及其制造方法以及显示设备 |
| KR102606277B1 (ko) | 2016-04-06 | 2023-11-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102642199B1 (ko) | 2016-04-07 | 2024-03-05 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CN109843856B (zh) | 2016-05-18 | 2023-05-02 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
| JP7044375B2 (ja) | 2016-05-31 | 2022-03-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｐｔｐｎ１１の複素環式阻害剤 |
| EA202092442A3 (ru) * | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR102666178B1 (ko) | 2016-06-07 | 2024-05-14 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| AU2017283769B2 (en) | 2016-06-14 | 2019-08-15 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| CN109661228A (zh) | 2016-06-20 | 2019-04-19 | 库拉肿瘤学公司 | 用erk抑制剂治疗鳞状细胞癌 |
| US20180002604A1 (en) | 2016-06-30 | 2018-01-04 | Merck Patent Gmbh | Liquid-crystalline medium |
| PH12019500056B1 (en) * | 2016-07-12 | 2024-01-31 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| US11299673B2 (en) | 2016-08-12 | 2022-04-12 | Merck Patent Gmbh | Liquid-crystal medium |
| KR102721990B1 (ko) | 2016-08-16 | 2024-10-29 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| EP3500570B1 (en) | 2016-08-19 | 2022-10-05 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| JP6589795B2 (ja) | 2016-09-27 | 2019-10-16 | 信越化学工業株式会社 | スルホニウム塩、レジスト組成物及びパターン形成方法 |
| WO2018060110A1 (en) | 2016-09-28 | 2018-04-05 | Merck Patent Gmbh | Polymerisable liquid crystal material and polymerised liquid crystal film |
| KR102394146B1 (ko) | 2016-09-29 | 2022-05-09 | 스미또모 가가꾸 가부시키가이샤 | 발광 소자 |
| EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| KR102506326B1 (ko) | 2016-10-13 | 2023-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Ror 감마 조정제로서의 헤테로시클릭 술폰 |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| EA201991128A1 (ru) | 2016-11-09 | 2019-10-31 | ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ | |
| US20180177784A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3048217A1 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EP3568204B1 (en) | 2017-01-10 | 2023-08-30 | Novartis AG | Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor |
| BR112019015075A2 (pt) | 2017-01-23 | 2020-03-10 | Revolution Medicines, Inc. | Compostos bicíclicos como inibidores de shp2 alostéricos |
| SG11201906412SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors |
| KR20190115012A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 헤테로사이클릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| KR20190115013A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 헤테로아릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| WO2018172984A1 (en) | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| KR102395784B1 (ko) | 2017-03-27 | 2022-05-10 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| KR102461719B1 (ko) | 2017-05-23 | 2022-11-01 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| WO2018230595A1 (ja) | 2017-06-14 | 2018-12-20 | 富士フイルム株式会社 | 組成物、膜、レンズ、固体撮像素子、化合物 |
| KR20180137311A (ko) | 2017-06-16 | 2018-12-27 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| WO2019002173A1 (en) | 2017-06-26 | 2019-01-03 | Esteve Pharmaceuticals, S.A. | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| GB201712110D0 (en) | 2017-07-27 | 2017-09-13 | Thomas Helledays Stiftelse För Medicinsk Forskning | New compounds and uses |
| KR20190014187A (ko) | 2017-07-27 | 2019-02-12 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함하는 유기 발광 소자 |
| JP7346015B2 (ja) | 2017-09-06 | 2023-09-19 | 住友化学株式会社 | 発光素子 |
| JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ，インコーポレイテッド | がんを治療するためのｓｈｐ２阻害剤組成物および方法 |
| CN118684652A (zh) | 2017-09-11 | 2024-09-24 | 克鲁松制药公司 | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 |
| WO2019067843A1 (en) | 2017-09-29 | 2019-04-04 | Relay Therapeutics, Inc. | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 |
| WO2019063585A1 (en) | 2017-09-29 | 2019-04-04 | Merck Patent Gmbh | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID CRYSTAL DISPLAY DEVICES |
| KR102526756B1 (ko) | 2017-09-29 | 2023-04-27 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| KR102518722B1 (ko) | 2017-11-21 | 2023-04-07 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| CA3084058A1 (en) | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| EP4335512A3 (en) | 2017-12-22 | 2024-06-12 | HiberCell, Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2019136442A1 (en) | 2018-01-08 | 2019-07-11 | Kleo Pharmaceuticals, Inc. | Cd16a binding agents and uses thereof |
| KR102595918B1 (ko) | 2018-01-18 | 2023-11-14 | 삼성디스플레이 주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 상기 유기 발광 소자를 포함한 유기 발광 장치 |
| CN110066276B (zh) | 2018-01-24 | 2020-09-18 | 上海璎黎药业有限公司 | 芳香杂环化合物、其中间体、制备方法、药物组合物和应用 |
| CN110066277B (zh) | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
| KR102824606B1 (ko) | 2018-02-13 | 2025-06-25 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 표시 장치 |
| MA51845A (fr) | 2018-02-13 | 2020-12-23 | Shanghai Blueray Biopharma Co Ltd | Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application |
| WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| KR102753101B1 (ko) | 2018-03-02 | 2025-01-09 | 오츠카 세이야쿠 가부시키가이샤 | 약제학적 화합물 |
| EP3537495B1 (en) | 2018-03-08 | 2025-02-12 | Samsung Display Co., Ltd. | Organic light-emitting device |
| EP3537493B1 (en) | 2018-03-09 | 2024-07-31 | Samsung Display Co., Ltd | Electronic apparatus |
| CN117263942A (zh) | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
| KR102724968B1 (ko) | 2018-03-21 | 2024-10-31 | 수조우 푸허 바이오파마 컴퍼니 리미티드 | Shp2 억제제 및 이의 용도 |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| CN108794485B (zh) | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | 一类toll样受体调节剂、其药物组合物、制备方法与用途 |
| JP7297871B2 (ja) | 2018-05-02 | 2023-06-26 | ナビール ファーマ，インコーポレイティド | Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター |
| CN110492006B (zh) | 2018-05-14 | 2020-06-12 | 江苏三月光电科技有限公司 | 一种基于含硼有机化合物的电致发光器件 |
| CN108840886A (zh) | 2018-06-22 | 2018-11-20 | 南京工业大学 | 一种铂配合物蓝光材料以及有机发光器件 |
| SG11202100719YA (en) | 2018-07-24 | 2021-02-25 | Taiho Pharmaceutical Co Ltd | Heterobicyclic compounds for inhibiting the activity of shp2 |
| CN108863982B (zh) | 2018-08-04 | 2022-02-01 | 南昌航空大学 | 一种吩噻嗪/吩恶嗪类化合物的有机电合成方法 |
| US11518770B2 (en) | 2018-08-06 | 2022-12-06 | Purdue Research Foundation | Sesquiterpenoid analogs |
| WO2020033828A1 (en) | 2018-08-10 | 2020-02-13 | Board Of Regents, The University Of Texas System | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| CA3113379A1 (en) | 2018-09-29 | 2020-04-02 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| EP3856744A1 (en) | 2018-09-29 | 2021-08-04 | Novartis AG | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
| CN113473990A (zh) | 2018-10-08 | 2021-10-01 | 锐新医药公司 | 用于治疗癌症的shp2抑制剂组合物 |
-
2019
- 2019-09-17 WO PCT/US2019/051592 patent/WO2020061103A1/en not_active Ceased
- 2019-09-17 FI FIEP19779687.3T patent/FI3853234T3/fi active
- 2019-09-17 WO PCT/US2019/051590 patent/WO2020061101A1/en not_active Ceased
- 2019-09-17 AU AU2019344899A patent/AU2019344899B2/en active Active
- 2019-09-17 CA CA3113234A patent/CA3113234A1/en active Pending
- 2019-09-17 CR CR20210175A patent/CR20210175A/es unknown
- 2019-09-17 EP EP19779687.3A patent/EP3853234B1/en active Active
- 2019-09-17 EP EP19779686.5A patent/EP3853233A1/en not_active Withdrawn
- 2019-09-17 ES ES19779687T patent/ES3036496T3/es active Active
- 2019-09-17 CN CN201980074583.3A patent/CN113227103B/zh active Active
- 2019-09-17 AU AU2019344897A patent/AU2019344897B2/en active Active
- 2019-09-17 JP JP2021539487A patent/JP7337174B2/ja active Active
- 2019-09-17 US US17/277,293 patent/US11459340B2/en active Active
- 2019-09-17 MX MX2021003158A patent/MX2021003158A/es unknown
- 2019-09-17 BR BR112021005082-5A patent/BR112021005082A2/pt unknown
- 2019-09-17 KR KR1020217011213A patent/KR102834408B1/ko active Active
- 2019-09-17 KR KR1020217011212A patent/KR20210060555A/ko active Pending
- 2019-09-17 CA CA3113233A patent/CA3113233A1/en active Pending
- 2019-09-17 SG SG11202102679QA patent/SG11202102679QA/en unknown
- 2019-09-17 JP JP2021539488A patent/JP7542538B2/ja active Active
- 2019-09-17 TW TW108133442A patent/TWI827677B/zh active
- 2019-09-17 PL PL19779687.3T patent/PL3853234T3/pl unknown
- 2019-09-17 DK DK19779687.3T patent/DK3853234T3/da active
- 2019-09-17 PT PT197796873T patent/PT3853234T/pt unknown
- 2019-09-17 CN CN201980074211.0A patent/CN112996795B/zh active Active
- 2019-09-17 US US16/573,900 patent/US20200115389A1/en not_active Abandoned
-
2020
- 2020-05-12 US US15/930,309 patent/US10894797B2/en active Active
- 2020-09-18 US US17/025,790 patent/US11518772B2/en active Active
- 2020-10-19 US US17/074,337 patent/US11034705B2/en active Active
-
2021
- 2021-03-15 CL CL2021000628A patent/CL2021000628A1/es unknown
- 2021-03-17 PH PH12021550604A patent/PH12021550604A1/en unknown
- 2021-03-17 SA SA521421505A patent/SA521421505B1/ar unknown
- 2021-04-09 CO CONC2021/0004436A patent/CO2021004436A2/es unknown
-
2022
- 2022-11-01 US US18/051,679 patent/US12264167B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7337174B2 (ja) | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 | |
| US20250018049A1 (en) | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway | |
| US20240287100A1 (en) | Alkylidene derivatives as kras inhibitors | |
| WO2024091409A1 (en) | Tricyclic derivatives as kras inhibitors | |
| EA031573B1 (ru) | N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2 | |
| WO2023249970A1 (en) | Bifunctional compounds containing pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| US20260021095A1 (en) | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | |
| WO2023250029A1 (en) | Bifunctional compounds containing substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| WO2022015670A1 (en) | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors | |
| EA044940B1 (ru) | Производные конденсированного трициклического кольца в качестве ингибиторов фосфатазы с доменом гомологии src2 | |
| WO2025212828A1 (en) | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway | |
| WO2025117981A1 (en) | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| WO2026011344A1 (en) | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway | |
| HK40058474B (zh) | 作为src同源-2磷酸酶抑制剂的三取代的杂芳基衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-5-5-R10-R17-oth-X000 |